Effects of Exenatide in Type 2 Diabetic Patients With Congestive Heart Failure

NCT00766857 · Completed

Last updated 2026-05-28

This clinical trial tests the effects of the medication exenatide in adults with both type 2 diabetes and congestive heart failure to evaluate changes in heart function using cardiac MRI.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 27 people

Who can join Ages 18+ · all sexes Healthy volunteers accepted.

Timeline Started 2009-05 · est. completion 2012-12

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT00766857 ↗

Description as written by the study sponsor.

The purpose of this study is to determine if exenatide will improve global cardiac function in patients with type 2 diabetes mellitus and congestive heart failure, by favorable effects on cardiac metabolism leading to improvement of cardiac efficiency.

Treatments tested

exenatide also known as exenatide-Byetta Drug

Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
Insulin glargine also known as insulin glargine-Lantus Drug

Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.

Main thing measured	Cardiac Magnetic Resonance (CMR) will be used to assess global cardiac function (LV ejection fraction).
Sponsor	Amsterdam UMC, location VUmc
Conditions studied	Type 2 Diabetes Mellitus, Congestive Heart Failure
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00766857 ↗